Galena price target raised to $9 from $6 at Maxim
fly on the wall
2 hours ago
Maxim raised its price target for Galena shares to $9 citing increased confidence in the developmentpipeline after the company said it started enrollment of a phase II trial for its second anti-cancer agent GALE-301. The firm reiterates a Buy rating on the stock.